Modified antimir-138 oligonucleotides
AssigneeAgency for Science, Technology and Research
InventorPrabha Sampath
Life of this patent
Estimating the term…
Abstract
Disclosed is a modified oligonucleotide capable of reducing or inhibiting one or more activities miR-138. The modified oligonucleotide may comprise at least one locked nucleic acid (LNA) and wherein the oligonucleotide is substantially complementary to a nucleotide sequence of miR-138. Also disclosed are pharmaceutical compositions comprising the oligonucleotides, methods of using the oligonucleotides and uses thereof.
Claims3
An oligonucleotide comprising one of the sequences selected from the group consisting of 5′-mC*mG*G*mCCmUmGA mUTmCAmCmAAmC AmCCmA*G*mC*mU-3′ (SEQ ID NO:
- 13), and 5′-mC*mG*mG*mCmCTmGAmUTmCAmCAmACmACmCmA*mG*mC*mU-3′ (SEQ ID NO:
- 10), wherein m is a 2′-O-methylation, * is a phosphorothioate linkage and underlined nucleotides represent a locked nucleic acid modification.
A pharmaceutical composition comprising an effective amount of an oligonucleotide comprising one of the sequences selected from the group consisting of 5′-mC*mG*G*mCCmUmGA mUTmCAmCmAAmC AmCCmA*G*mC*mU-3′ (SEQ ID NO:
- 13), and 5′-mC*mG*mG*mCmCTmGAmUTmCAmCAmACmACmCmA*mG*mC*mU-3′ (SEQ ID NO:
- 10), wherein m is a 2′-O-methylation, * is a phosphorothioate linkage and underlined nucleotides represent a locked nucleic acid modification, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier or diluent.
Dependencies are inferred from the claim text.